Clinical trials: Thymic Epithelial Tumor
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Thymic Epithelial Tumor
Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging
The aim of this study is to analyze aquaporins expression of thymic epithelial tumors and to compare them with apparent diffusion coefficient(ADC) from ultra-high b-values, and to test a possibility of use of ADCuh to identify…
- Trial name
- NCT03212027
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
NSCLC, Non-Small Cell Lung Cancer
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic…
- Conditions
- NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT07902921
- Testing
- STAR0602, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pleural Metastases, Breast Cancer
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Cancers that have spread to the inner lining of the chest are classified as Stage IV and bear a poor prognosis. Surgery is rarely an option, with palliative chemotherapy and/or radiation therapy the only treatment options.
- Conditions
- Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer
- Trial name
- NCT01163552
- Testing
- Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors
the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis.
- Trial name
- NCT03288662
- Testing
- CT and histopathological classification
- Volunteers
- 2 people
- Sponsor
- Military Hospital 103
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Background: Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors
- Trial name
- NCT02146170
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Carcinoma, Thymoma
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
This is a multicentric study. All patients with TET (thymic epithelial tumors) of any histological type will participate in the study.
- Trial name
- RELEVENT (NCT03921671)
- Testing
- Ramucirumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Claudia Proto
Thymic Epithelial Tumor, Thymoma
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or…
- Conditions
- Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma, Pleural Metastasis
- Trial name
- NCT07328074
- Testing
- Patients with thymic epithelial tumors with pleural metastasis or recurrence who undergo extended thymectomy with electrocautery resection of pleural metastases followed by two cycles of hyperthermic, Hyperthermic Intrathoracic Chemotherapy (HITHOC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Thymoma and Thymic Carcinoma
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
This randomized controlled trial compares 6 versus 3 cycles of neoadjuvant chemotherapy in patients with potentially resectable locally advanced thymic epithelial tumors (TETs, WHO type AB/B/C, AJCC TNM stage IIIA-IVA).
- Trial name
- NCT07463313
- Testing
- Cyclophosphamide, Doxorubicin, and Cisplatin (CAP), nab-Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging.
- Conditions
- Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06141369
- Testing
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Thymic Epithelial Tumors
A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy.
- Trial name
- NCT02607631
- Testing
- Pembrolizumab
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Thymus Epithelial Tumor, Proton Radiotherapy
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies.
- Conditions
- Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
- Trial name
- NCT06311968
- Testing
- Proton radiotherapy, combined platinum based chemotherapy
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Jian Chen
Thymus Neoplasms, Thymic Epithelial Tumor
Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
This is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors.
- Conditions
- Thymus Neoplasms, Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma
- Trial name
- THOR (NCT07693855)
- Testing
- Hypofractionated Adjuvant Proton Therapy, Hypofractionated Adjuvant Photon Radiation Therapy
- Where
- 3 sites in Taiwan
- Volunteers
- 69 people
- Sponsor
- National Taiwan University Hospital
Thymic Epithelial Tumor, Radiotherapy Side Effect
Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection.
- Conditions
- Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy
- Trial name
- NCT06311955
- Testing
- Carbon ion radiotherapy, combined with platinum-based regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jian Chen
Cancer
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
- Trial name
- IMMUNO-TET (NCT05558644)
- Testing
- single arm for all patients
- Where
- 3 sites in France
- Volunteers
- 50 people
- Sponsor
- Institut Curie
Cancer
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.
- Trial name
- NCT00066404
- Testing
- recombinant adenovirus-hIFN-beta
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc